Analytical and Bioanalytical Chemistry

, Volume 396, Issue 8, pp 2899–2908 | Cite as

Quantification of urinary AICAR concentrations as a matter of doping controls

  • Andreas Thomas
  • Simon Beuck
  • Jens Christian Eickhoff
  • Sven Guddat
  • Oliver Krug
  • Matthias Kamber
  • Wilhelm Schänzer
  • Mario Thevis
Paper in Forefront

Abstract

Influencing the endurance in elite sports is one of the key points in modern sports science. Recently, a new class of prohibited substances reached in the focus of doping control laboratories and their misuse was classified as gene doping. The adenosine monophosphate activated protein kinase activator 5-amino-4-imidazolecarboxyamide ribonucleoside (AICAR) was found to significantly enhance the endurance even in sedentary mice after treatment. Due to endogenous production of AICAR in healthy humans, considerable amounts were present in the circulation and, thus, were excreted into urine. Considering these facts, the present study was initiated to fix reference values of renally cleared AICAR in elite athletes. Therefore a quantitative analytical method by means of isotope-dilution liquid chromatography (analytical column: C6-phenyl) coupled to tandem mass spectrometry, after a sample preparation consisting of a gentle dilution of native urine, was developed. Doping control samples of 499 athletes were analysed, and AICAR concentrations in urine were determined. The mean AICAR value for all samples was 2,186 ng/mL with a standard deviation of 1,655 ng/mL. Concentrations were found to differ depending on gender, type of sport and type of sample collection (in competition/out of competition). The method was fully validated for quantitative purposes considering the parameters linearity, inter- (12%, 7% and 10%) and intraday precision (14%, 9% and 12%) at low, mid and high concentration, robustness, accuracy (approx. 100%), limit of quantification (100 ng/mL), stability and ion suppression effects, employing an in-house synthesised 13C5-labelled AICAR as internal standard.

Urinary AICAR concentrations (ng/mL)

Keywords

Gene doping Sports drug testing LC-MS/M Mass spectrometry 

References

  1. 1.
    Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM (2008) AMPK and PPARdelta agonists are exercise mimetics. Cell 134:405–415CrossRefGoogle Scholar
  2. 2.
    Thevis M, Thomas A, Kohler M, Beuck S, Schänzer W (2009) Emerging drugs: mechanism of action, mass spectrometry and doping control analysis. J Mass Spectrom 44:442–460CrossRefGoogle Scholar
  3. 3.
    Barre L, Richardson C, Hirshman MF, Brozinick J, Fiering S, Kemp BE, Goodyear LJ, Witters LA (2007) Genetic model for the chronic activation of skeletal muscle AMP-activated protein kinase leads to glycogen accumulation. Am J Physiol Endocrinol Metab 292:E802–E811CrossRefGoogle Scholar
  4. 4.
    Goodyear LJ (2008) The exercise pill—too good to be true? N Engl J Med 359:1842–1844CrossRefGoogle Scholar
  5. 5.
  6. 6.
    Marie S, Heron B, Bitoun P, Timmerman T, Van Den Berghe G, Vincent MF (2004) AICA-ribosiduria: a novel, neurologically devastating inborn error of purine biosynthesis caused by mutation of ATIC. Am J Hum Genet 74:1276–1281CrossRefGoogle Scholar
  7. 7.
    Baggott JE, Morgan SL, Sams WM, Linden J (1999) Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis. Arch Dermatol 135:813–817CrossRefGoogle Scholar
  8. 8.
    Hornik P, Vyskocilova P, Friedecky D, Adam T (2006) Diagnosing AICA-ribosiduria by capillary electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 843:15–19CrossRefGoogle Scholar
  9. 9.
    Schlimme E, Boos KS, Hagemeier E, Kemper K, Meyer U, Hobler H, Schnelle T, Weise M (1986) Direct clean-up and analysis of ribonucleosides in physiological fluids. J Chromatogr 378:349–360CrossRefGoogle Scholar
  10. 10.
  11. 11.
    Saito Y, Zevaco TA, Agrofoglio LA (2002) Chemical synthesis of C-13 labeled anti-HIV nucleosides as mass-internal standards. Tetrahedron 58:9593–9603CrossRefGoogle Scholar
  12. 12.
    Kohyama N, Yamamoto Y (2003) A facile synthesis of AICAR from inosine. Synthesis-Stuttgart 2639–2642Google Scholar
  13. 13.
    Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003) Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 75:3019–3030CrossRefGoogle Scholar
  14. 14.
    Azzalini A, Capitanio A (1999) Statistical applications of the multivariate skew normal distribution. J Roy Statist Soc 61:579–602CrossRefGoogle Scholar
  15. 15.
    Neter J, Wasserman W, Kutner MH, Nachtsheim C (2005) Applied linear statistical models, 4th edn. WCB McGraw-Hill, BostonGoogle Scholar
  16. 16.
    Dixon R, Fujitaki J, Sandoval T, Kisicki J (1993) Acadesine (AICA-riboside): disposition and metabolism of an adenosine-regulating agent. J Clin Pharmacol 33:955–958Google Scholar
  17. 17.
    Dixon R, Gourzis J, McDermott D, Fujitaki J, Dewland P, Gruber H (1991) AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. J Clin Pharmacol 31:342–347Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Andreas Thomas
    • 1
  • Simon Beuck
    • 1
  • Jens Christian Eickhoff
    • 2
  • Sven Guddat
    • 1
  • Oliver Krug
    • 1
  • Matthias Kamber
    • 3
  • Wilhelm Schänzer
    • 1
  • Mario Thevis
    • 1
  1. 1.Institute of Biochemistry, Center for Preventive Doping ResearchGerman Sport University CologneCologneGermany
  2. 2.Department of StatisticsColorado State UniversityFort CollinsUSA
  3. 3.Department of Doping PreventionFederal Office of SportsBernSwitzerland

Personalised recommendations